JP2009502800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502800A5 JP2009502800A5 JP2008522947A JP2008522947A JP2009502800A5 JP 2009502800 A5 JP2009502800 A5 JP 2009502800A5 JP 2008522947 A JP2008522947 A JP 2008522947A JP 2008522947 A JP2008522947 A JP 2008522947A JP 2009502800 A5 JP2009502800 A5 JP 2009502800A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polyethylene glycol
- polypeptide
- seq
- encoded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70095105P | 2005-07-20 | 2005-07-20 | |
| US60/700,951 | 2005-07-20 | ||
| US77126006P | 2006-02-08 | 2006-02-08 | |
| US60/771,260 | 2006-02-08 | ||
| PCT/US2006/028106 WO2007013944A2 (en) | 2005-07-20 | 2006-07-20 | Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502800A JP2009502800A (ja) | 2009-01-29 |
| JP2009502800A5 true JP2009502800A5 (enExample) | 2009-09-03 |
| JP4987001B2 JP4987001B2 (ja) | 2012-07-25 |
Family
ID=37683787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522947A Active JP4987001B2 (ja) | 2005-07-20 | 2006-07-20 | 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20070020227A1 (enExample) |
| EP (1) | EP1909821A2 (enExample) |
| JP (1) | JP4987001B2 (enExample) |
| AU (1) | AU2006272937A1 (enExample) |
| CA (1) | CA2616004A1 (enExample) |
| IL (1) | IL188357A0 (enExample) |
| WO (1) | WO2007013944A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271786A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1931704B1 (en) | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
| JP2009115776A (ja) * | 2007-07-11 | 2009-05-28 | Ngk Spark Plug Co Ltd | アンモニアガスセンサ |
| JP5083898B2 (ja) * | 2007-07-11 | 2012-11-28 | 日本特殊陶業株式会社 | アンモニアガスセンサ |
| RU2496514C2 (ru) * | 2008-06-05 | 2013-10-27 | Займоджинетикс, Инк. | Применение пэгилированных интерферонов типа iii для лечения гепатита с |
| US20100316608A1 (en) * | 2009-06-15 | 2010-12-16 | Vijayaprakash Suppiah | Method of Determining A Response To Treatment With Immunomodulatory Composition |
| FR2975185A1 (fr) * | 2011-05-12 | 2012-11-16 | Univ Claude Bernard Lyon | Procede de determination in vitro de la presence d'une sclerose en plaques |
| CN104045704B (zh) * | 2013-03-11 | 2016-08-10 | 中国医学科学院基础医学研究所 | PEG化重组人IFN-λ1、其制备方法和用途 |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN103923209B (zh) * | 2014-05-13 | 2016-06-22 | 北京凯因科技股份有限公司 | 一种Lambda干扰素突变体及聚乙二醇衍生物 |
| CN105085658B (zh) * | 2014-05-14 | 2019-12-24 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体及聚乙二醇衍生物 |
| DE102015001902A1 (de) * | 2015-02-18 | 2016-08-18 | Continental Reifen Deutschland Gmbh | Verfahren zur Verbesserung der Haftung zwischen einem Verstärkungselement und einem elastomeren Matrixmaterial |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| KR20180110127A (ko) | 2016-02-19 | 2018-10-08 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| JP2019531729A (ja) * | 2016-09-30 | 2019-11-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 変異体ｉｉｉ型インターフェロン及びシンセカイン |
| US20220378878A1 (en) * | 2019-12-20 | 2022-12-01 | The Council Of The Queensland Institute Of Medical Research | Treatment of gastrointestinal disease |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI86558C (fi) | 1980-01-08 | 1992-09-10 | Biogen Inc | Dna- sekvenser, rekombinant-dna- molekyler och foerfaranden foer framstaellning av humant interferon av -typ och val av dna-sekvensen. |
| US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6468776B1 (en) * | 2000-03-03 | 2002-10-22 | Zymogenetics, Inc. | Human serine protease |
| AU2001271589A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
| AU2001271786A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| EP2298789B1 (en) | 2000-09-08 | 2012-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
| US7038032B2 (en) * | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| CN100482684C (zh) * | 2001-04-20 | 2009-04-29 | 津莫吉尼蒂克斯公司 | 细胞因子蛋白质家族 |
| PL373008A1 (en) * | 2001-05-10 | 2005-08-08 | Immunex Corporation | Cytokine polypeptides |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| BR0309401A (pt) * | 2002-04-19 | 2007-02-21 | Zymogenetics Inc | polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| CA2558829C (en) | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| AU2005266892B2 (en) * | 2004-07-29 | 2011-03-03 | Bristol-Myers Squibb Company | Use of IL-28 and IL-29 to treat cancer and autoimmune disorders |
| CN1305902C (zh) | 2004-11-25 | 2007-03-21 | 汕头大学医学院 | 一种人白细胞介素29的生产方法及重组il－29工程菌 |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| EP1931704B1 (en) * | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
-
2006
- 2006-07-20 AU AU2006272937A patent/AU2006272937A1/en not_active Abandoned
- 2006-07-20 CA CA002616004A patent/CA2616004A1/en not_active Abandoned
- 2006-07-20 JP JP2008522947A patent/JP4987001B2/ja active Active
- 2006-07-20 US US11/489,894 patent/US20070020227A1/en not_active Abandoned
- 2006-07-20 WO PCT/US2006/028106 patent/WO2007013944A2/en not_active Ceased
- 2006-07-20 EP EP06787912A patent/EP1909821A2/en not_active Withdrawn
-
2007
- 2007-12-24 IL IL188357A patent/IL188357A0/en unknown
-
2009
- 2009-11-02 US US12/611,067 patent/US20100298230A1/en not_active Abandoned
-
2011
- 2011-03-07 US US13/042,210 patent/US8313739B2/en active Active
-
2012
- 2012-04-05 US US13/440,066 patent/US20120251488A1/en not_active Abandoned
-
2013
- 2013-08-22 US US13/973,127 patent/US20140044676A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502800A5 (enExample) | ||
| JP2009502803A5 (enExample) | ||
| JP2008508310A5 (enExample) | ||
| JP2008540565A5 (enExample) | ||
| JP2012255007A5 (enExample) | ||
| JP2005177500A5 (enExample) | ||
| JP2010505444A5 (enExample) | ||
| JP2010534486A5 (enExample) | ||
| NZ592250A (en) | Modified animal erythropoietin polypeptides and their uses | |
| JP2012532601A5 (enExample) | ||
| EP2174668A3 (en) | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | |
| JP2009514172A5 (enExample) | ||
| JP2006527780A5 (enExample) | ||
| JP2006006329A5 (enExample) | ||
| JP2004115529A5 (enExample) | ||
| IL183165A (en) | Polypeptides derived from the extracellular protein of the trem-1 protein and which can be used as antagonists of the trem-1 protein, preparations containing them and their uses for the preparation of a drug for the treatment of sepsis, septic shock and sepsis-like conditions | |
| JP2008503230A5 (enExample) | ||
| WO2007136504A3 (en) | Medical devices having bioactive surfaces | |
| JP2012517818A5 (enExample) | ||
| JP2013538864A5 (enExample) | ||
| JP2009503174A5 (enExample) | ||
| JP2013535428A5 (enExample) | ||
| WO2008113515A3 (en) | huTNFR1 SELECTIVE ANTAGONISTS | |
| WO2008054597A3 (en) | Tyrosine phosphorylation sites | |
| JP2007075118A5 (enExample) |